LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eli Lilly (LLY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, robust growth in GLP-1 sales, and significant purchases by Congress members indicate a favorable long-term outlook.
The MACD histogram is negative (-6.125) but contracting, indicating potential stabilization. RSI is neutral at 25.149, and moving averages are converging, suggesting no clear trend. The stock is trading near its S1 support level of 900.959, which could provide a buying opportunity.
Strong financial performance in Q4 2025, with revenue up 42.56% YoY and net income up 50.52% YoY.
Robust growth in GLP-1 drug sales, contributing to 56% of total revenue in
Positive sentiment from Congress trading data, with $1.5M-$5.0M in purchases over the last 90 days.
Analysts maintain high price targets, ranging from $1,200 to $1,350, with multiple Buy ratings.
Insider selling has increased significantly (4519.16% over the last month).
HSBC downgraded the stock to Reduce, citing elevated expectations for the obesity market and potential pricing competition.
Technical indicators show no clear upward momentum, and the stock is trading near support levels.
In Q4 2025, Eli Lilly reported a revenue increase of 42.56% YoY to $19.29 billion, net income growth of 50.52% YoY to $6.64 billion, and EPS growth of 51.43% YoY to $7.39. Gross margin improved slightly to 82.52%.
The majority of analysts maintain a Buy or Outperform rating on LLY, with price targets ranging from $1,200 to $1,350. Analysts highlight the company's leadership in the GLP-1 market and transformative growth catalysts, though HSBC downgraded the stock to Reduce with a price target of $850, citing elevated market expectations and pricing pressures.
